Join Agendia at SABCS® 2021


Agendia at San Antonio Breast Cancer Symposium®

This year with the return to an in-person SABCS®, Agendia will be presenting new data on MammaPrint® and BluePrint®, sponsoring a case-based multidisciplinary discussion of the utility of our tests, hosting a patient advocacy event, along with many other activities. We hope to see you in San Antonio or virtually!

SABCS® 2021
Annual Meeting

Agendia will be showcasing MammaPrint and BluePrint live and virtually at booth #613.

Schedule a meeting

Agendia’s activities:

2021 SABCS® Product Theater:

  • Date: Tuesday, December 7, 2021 – 4:00 PM- 5:00 PM CT
  • Location: Henry B. Gonzalez Convention Center, Exhibit hall
  • Panel of Experts:
    • Joyce O’Shaughnessy, MD, Breast Medical Oncologist, Texas Oncology-Baylor Sammons Cancer Center
    • Jaime Alberty, MD, Breast Surgical Oncologist, Kings County Hospital at NYC Health + Hospitals,
    • Hannah Gilmore, MD, Pathologist, University Hospitals Cleveland Medical Center
  • Moderator:
    • William Audeh, MD, Breast Medical Oncologist, Chief Medical Officer Agendia, Inc.

The Launch of Agendia’s Patient-Focused Power Project

Join us for a panel discussion where patients will share their path to empowerment through information-gathering and self-advocacy following a breast cancer diagnosis moderated by Dr. Princess Thomas.

  • Date: Tuesday, December 7, 2021 – 7:30 PM- 9:00 PM CT
  • Location: Salon D Ballroom , Marriott Riverwalk, 889 E Market St, San Antonio, TX 78205
  • Beverages and desserts will be served
RSVP NOW

Spotlight Poster:

  • Title: Effect of pertuzumab plus neoadjuvant trastuzumab-based chemotherapy in early-stage HER2-positive breast cancer according to BluePrint molecularly defined breast cancer subtypesl
  • Poster #: PD15-07
  • Authors: Liefaard MC, van der Voort A, Sanders J, Vonk S, Horlings HM, Siesling S, de Munck L, van Leeuwen-Stok E, Kleijn M, Mittempergher L, Kuilman MM, Lips EH, Sonke GS
  • Session: Poster Session 15: Defining Molecular Markers of Resistance

Agendia’s Posters:

The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early-stage breast cancer

  • Authors: Ma CX, Maganini R, Whitworth P, Crozier JA, O’Shaughnessy J, Diab S, Lesnikoski B-A, Lee J, D’Abreo N, Mavromatis BH, Kelemen P, Pronin D, Abebe H, Bolner ML, Finn C, Blumencranz L, Audeh W, FLEX Investigators Group
  • Session: Ongoing Trials Poster Session 2: OT2-07-0
  • Poster #: OT2-07-01

Defining transcriptomic profiles of breast cancer with early lymph node metastases: a FLEX database sub-study

  • Authors: Budhathoki N, Fa’ak F, D’Abreo N, Dhage S, Soe PP, Holmes D, Haan J, Wang S, Dauer P, Menicucci A, Audeh W, Marks DK. FLEX Investigators Group
  • Session: Poster Session 2: Prognostic and Predictive Factors – Biomarkers Predicting Tx Response: Predictive Biomarkers – Other
  • Poster #: P2-08-06

Mammaprint and Blueprint identify genomic differences in HR+ HER2- breast cancers from young Black and White women

  • Authors: Reid S, Pal T, Mayer IA, Shu X-O, Tezak AL, Hoskins K, Sharma D, Robinson P, Wei J, Ruby J, Wang S, Haan J, Menicucci A, Audeh W, FLEX Investigators Group.
  • Session: Poster Session 3: Epidemiology, Risk, and prevention: Ethnic/Racial Aspects
  • Poster #: P3-14-11

Mammaprint and blueprint are prognostic of outcome following neoadjuvant chemotherapy

  • Authors: Chung AP, Srour M, Dadmanesh F, Kim S, Giuliano A, Wei J, Huynh Y, Wang S, Menicucci A, Audeh W.
  • Session: Poster Session 4: Prognostic and Predictive Factors – Other
  • Poster #: P4-07-32

Deciphering the inferior prognosis of young women with estrogen receptor-positive early-stage breast cancer through full transcriptome analysis: a FLEX database sub-study

  • Authors: Dhage S, Gendy M, D’Abreo N, Oratz R, Diab SG, Gadi VK, Graham C, Kuilman M, Wang S, Dauer P, Menicucci A, Audeh W, Marks DK., FLEX Investigators Group
  • Session: Poster Session 5: Tumor Cell and Molecular Biology: Molecular Profiles
  • Poster #: P5-07-05

Effect of pertuzumab plus neoadjuvant trastuzumab-based chemotherapy in early-stage HER2-positive breast cancer according to BluePrint molecularly defined breast cancer subtypes

  • Authors: Liefaard MC, van der Voort A, Sanders J, Vonk S, Horlings HM, Siesling S, de Munck L, van Leeuwen-Stok E, Kleijn M, Mittempergher L, Kuilman MM, Lips EH, Sonke GS.
  • Session: Poster Session 15: Defining Molecular Markers of Resistance
  • Poster #: PD15-07
  • This field is for validation purposes and should be left unchanged.

For the US, Puerto Rico, and South America

Agendia Inc. USA
22 Morgan
Irvine, CA 92618
(888) 321-2732
customercare@agendia.com


For outside the Americas

Agendia NV
Radarweg 60
1043 NT Amsterdam
The Netherlands
customerservice@agendia.com
+31 (0)20 462 1510